{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:40:40Z","timestamp":1783010440423,"version":"3.54.6"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04739-3","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T09:09:44Z","timestamp":1767690584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diagnosis and treatment of complement-mediated thrombotic microangiopathies: consensus of the Genetic Diseases Committee of the Chilean Society of Nephrology"],"prefix":"10.1186","volume":"27","author":[{"given":"Pilar","family":"Musalem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Bascur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo A.","family":"Sep\u00falveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Krall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lazcano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lica","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Grandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"issue":"17","key":"4739_CR1","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/nejmra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G. Atypical Hemolytic\u2013Uremic syndrome. N Engl J Med. 2009;361(17):1676\u201387. https:\/\/doi.org\/10.1056\/nejmra0902814.","journal-title":"N Engl J Med"},{"key":"4739_CR2","doi-asserted-by":"publisher","unstructured":"Goodship THJ, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2017;91(3):539\u201351. https:\/\/doi.org\/10.1016\/j.kint.2016.10.005.","DOI":"10.1016\/j.kint.2016.10.005"},{"key":"4739_CR3","doi-asserted-by":"publisher","unstructured":"L CM, L C. Terminal complement inhibitor Eculizumab in atypical Hemolytic\u2013Uremic syndrome. N Engl J Med. 2013;368(23):2169\u201381. https:\/\/doi.org\/10.1056\/nejmoa1208981.","DOI":"10.1056\/nejmoa1208981"},{"key":"4739_CR4","doi-asserted-by":"publisher","unstructured":"Maisons V, Duval A, Mesnard L, et al. Assessment of epidemiology and outcomes of adult patients with kidney-limited thrombotic microangiopathies. Kidney Int. 2024;105(5):1100\u201312. https:\/\/doi.org\/10.1016\/j.kint.2024.02.014.","DOI":"10.1016\/j.kint.2024.02.014"},{"issue":"6923","key":"4739_CR5","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/s0140-6736(56)90644-4","volume":"267","author":"Symmers WStC","year":"1956","unstructured":"Symmers WStC. Thrombotic microangiopathy histological diagnosis during life. Lancet. 1956;267(6923):592\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(56)90644-4.","journal-title":"Lancet"},{"key":"4739_CR6","doi-asserted-by":"publisher","unstructured":"Burwick RM, Moyle K, Java A, Gupta M, Differentiating, Hemolysis. Elevated liver Enzymes, and low platelet count syndrome and atypical hemolytic uremic syndrome in the postpartum period. Hypertension. 2021;78(3):760\u20138. https:\/\/doi.org\/10.1161\/hypertensionaha.121.17311.","DOI":"10.1161\/hypertensionaha.121.17311"},{"key":"4739_CR7","doi-asserted-by":"publisher","unstructured":"DONG J -F. Cleavage of ultra\u2010large von Willebrand factor by ADAMTS\u201013 under flow conditions. J Thromb Haemost. 2005;3(8):1710\u20136. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01360.x.","DOI":"10.1111\/j.1538-7836.2005.01360.x"},{"key":"4739_CR8","doi-asserted-by":"publisher","unstructured":"Levandovsky M, Harvey D, Lara P, Wun T. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients. J Hematol Oncol. 2008;1(1):23. https:\/\/doi.org\/10.1186\/1756-8722-1-23.","DOI":"10.1186\/1756-8722-1-23"},{"key":"4739_CR9","doi-asserted-by":"publisher","unstructured":"Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4(4):e157-e164. https:\/\/doi.org\/10.1016\/s2352-3026(17)30026-1.","DOI":"10.1016\/s2352-3026(17)30026-1"},{"key":"4739_CR10","doi-asserted-by":"publisher","unstructured":"Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic Purpura\u2013Hemolytic uremic syndrome. N Engl J Med. 1991;325(6):398\u2013403. https:\/\/doi.org\/10.1056\/nejm199108083250605.","DOI":"10.1056\/nejm199108083250605"},{"issue":"1","key":"4739_CR11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12882-025-04156-6","volume":"26","author":"MG Uriol-Rivera","year":"2025","unstructured":"Uriol-Rivera MG, Ernst FR, Booth JN 3rd, Comas \u00c0, Gasteyger C, Tomazos I, Lum C, Wang Y, \u00c1vila AI. PLASMIC score to aid diagnosis of aHUS: an analysis of C5 inhibitor clinical trials and the PINC AI healthcare database. BMC Nephrol. 2025;26(1):241.","journal-title":"BMC Nephrol"},{"issue":"3","key":"4739_CR12","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3390\/jcm11030648","volume":"11","author":"L Burguet","year":"2022","unstructured":"Burguet L, Taton B, Prezelin-Reydit M, et al. \u00adCreatinine ratio in thrombotic microangiopathies: A simple test to facilitate thrombotic thrombocytopenic purpura and hemolytic and uremic syndrome diagnosis. J Clin Med. 2022;11(3):648. https:\/\/doi.org\/10.3390\/jcm11030648.","journal-title":"J Clin Med"},{"key":"4739_CR13","doi-asserted-by":"publisher","unstructured":"Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB. Clinical course and the role of Shiga Toxin\u2013Producing Escherichia coli infection in the Hemolytic-Uremic syndrome in pediatric Patients, 1997\u20132000, in Germany and austria: A prospective study. J Infect Dis. 2002;186(4):493\u2013500. https:\/\/doi.org\/10.1086\/341940.","DOI":"10.1086\/341940"},{"key":"4739_CR14","doi-asserted-by":"publisher","unstructured":"Freedman SB, van de Kar NCAJ, Tarr PI. Shiga Toxin\u2013Producing Escherichia coli and the Hemolytic\u2013Uremic syndrome. N Engl J Med. 2023;389(15):1402\u201314. https:\/\/doi.org\/10.1056\/nejmra2108739.","DOI":"10.1056\/nejmra2108739"},{"key":"4739_CR15","doi-asserted-by":"publisher","unstructured":"Silva RL. da. Viral-associated thrombotic microangiopathies. HematolOncol Stem Cell Ther. 2011;4(2):51\u201359. https:\/\/doi.org\/10.5144\/1658-3876.2011.51.","DOI":"10.5144\/1658-3876.2011.51"},{"key":"4739_CR16","doi-asserted-by":"publisher","unstructured":"Vrecko MM, Veceric-Haler Z. Coronavirus disease 2019-Associated thrombotic microangiopathy. J Hematol. 2022;11(4):148\u201353. https:\/\/doi.org\/10.14740\/jh1019.","DOI":"10.14740\/jh1019"},{"key":"4739_CR17","doi-asserted-by":"publisher","unstructured":"Scobell RR, Kaplan BS, Copelovitch L. New insights into the pathogenesis of Streptococcus pneumoniae\u2013associated hemolytic uremic syndrome. Pediatr Nephrol. 2020;35(9):1585\u201391. https:\/\/doi.org\/10.1007\/s00467-019-04342-3.","DOI":"10.1007\/s00467-019-04342-3"},{"key":"4739_CR18","doi-asserted-by":"publisher","unstructured":"Kello N, Khoury LE, Marder G, Furie R, Zapantis E, Horowitz DL. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature. Semin Arthritis Rheum. 2019;49(1):74\u201383. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.11.005.","DOI":"10.1016\/j.semarthrit.2018.11.005"},{"key":"4739_CR19","doi-asserted-by":"publisher","unstructured":"Fu Y, Chen Z, Chen J et al. Eculizumab Improves Renal Survival in Complement-Mediated TMA Secondary to SLE. Mayo Clin Proc. Published online 2024. https:\/\/doi.org\/10.1016\/j.mayocp.2024.10.001.","DOI":"10.1016\/j.mayocp.2024.10.001"},{"key":"4739_CR20","doi-asserted-by":"publisher","unstructured":"Gupta M, Feinberg BB, Burwick RM. Thrombotic microangiopathies of pregnancy: Differential diagnosis. Pregnancy Hypertens. 2018;12:29\u201334. https:\/\/doi.org\/10.1016\/j.preghy.2018.02.007.","DOI":"10.1016\/j.preghy.2018.02.007"},{"key":"4739_CR21","doi-asserted-by":"publisher","unstructured":"Morton JM, George JN. Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer. J Oncol Pr. 2016;12(6):523\u201330. https:\/\/doi.org\/10.1200\/jop.2016.012096.","DOI":"10.1200\/jop.2016.012096"},{"key":"4739_CR22","doi-asserted-by":"publisher","unstructured":"Lechner K, Obermeier HL. Cancer-Related microangiopathic hemolytic anemia. Medicine. 2012;91(4):195\u2013205. https:\/\/doi.org\/10.1097\/md.0b013e3182603598.","DOI":"10.1097\/md.0b013e3182603598"},{"issue":"3","key":"4739_CR23","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.kint.2016.09.045","volume":"91","author":"A Ravindran","year":"2017","unstructured":"Ravindran A, Go RS, Fervenza FC, Sethi S. Thrombotic microangiopathy associated with monoclonal gammopathy. Kidney Int. 2017;91(3):691\u20138. https:\/\/doi.org\/10.1016\/j.kint.2016.09.045.","journal-title":"Kidney Int"},{"issue":"12","key":"4739_CR24","doi-asserted-by":"publisher","first-page":"E373","DOI":"10.1002\/ajh.27104","volume":"98","author":"S Khan","year":"2023","unstructured":"Khan S, George JN, Nusrat S. Drug-induced thrombotic microangiopathy and thrombotic thrombocytopenic purpura: A systematic review, 2018\u20132023. Am J Hematol. 2023;98(12):E373\u20135. https:\/\/doi.org\/10.1002\/ajh.27104.","journal-title":"Am J Hematol"},{"key":"4739_CR25","doi-asserted-by":"publisher","unstructured":"Reese JA, Bougie DW, Curtis BR, et al. Drug-induced thrombotic microangiopathy: experience of the Oklahoma registry and the bloodcenter of Wisconsin. Am J Hematol. 2015;90(5):406\u201310. https:\/\/doi.org\/10.1002\/ajh.23960.","DOI":"10.1002\/ajh.23960"},{"issue":"4","key":"4739_CR26","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/bjh.18577","volume":"201","author":"J Schofield","year":"2023","unstructured":"Schofield J, Hosseinzadeh S, Burton K, et al. Drug-induced thrombotic thrombocytopenic purpura: A systematic review and review of European and North American pharmacovigilance data. Br J Haematol. 2023;201(4):766\u201373. https:\/\/doi.org\/10.1111\/bjh.18577.","journal-title":"Br J Haematol"},{"key":"4739_CR27","doi-asserted-by":"publisher","unstructured":"Chatzikonstantinou T, Gavriilaki M, Anagnostopoulos A, Gavriilaki E. An update in Drug-Induced thrombotic microangiopathy. Front Med. 2020;7:212. https:\/\/doi.org\/10.3389\/fmed.2020.00212.","DOI":"10.3389\/fmed.2020.00212"},{"key":"4739_CR28","doi-asserted-by":"publisher","unstructured":"Mazzierli T, Allegretta F, Maffini E, Allinovi M. Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management. Front Pharmacol. 2023;13:1088031. https:\/\/doi.org\/10.3389\/fphar.2022.1088031.","DOI":"10.3389\/fphar.2022.1088031"},{"key":"4739_CR29","doi-asserted-by":"publisher","unstructured":"Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transpl. 2010;10(7):1517\u201323. https:\/\/doi.org\/10.1111\/j.1600-6143.2010.03156.x.","DOI":"10.1111\/j.1600-6143.2010.03156.x"},{"key":"4739_CR30","doi-asserted-by":"publisher","unstructured":"Rondeau E, Scully M, Ariceta G, et al. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int. 2020;97(6):1287\u201396. https:\/\/doi.org\/10.1016\/j.kint.2020.01.035.","DOI":"10.1016\/j.kint.2020.01.035"},{"key":"4739_CR31","doi-asserted-by":"publisher","unstructured":"\u00c1vila A, Cao M, Espinosa M, Manrique J, Morales E. Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults. Front Med. 2023;10:1264310. https:\/\/doi.org\/10.3389\/fmed.2023.1264310.","DOI":"10.3389\/fmed.2023.1264310"},{"key":"4739_CR32","doi-asserted-by":"publisher","unstructured":"Cavero T, Au\u00f1\u00f3n P, Caravaca-Font\u00e1n F, Trujillo H, Arjona E, Morales E, Guill\u00e9n E, Blasco M, Rabasco C, Espinosa M, Blanco M, Rodr\u00edguez-Magari\u00f1os C, Cao M, \u00c1vila A, Huerta A, Rubio E, Cabello V, Barros X, Goicoechea de Jorge E, Rodr\u00edguez de C\u00f3rdoba, Praga S. M. Thrombotic microangiopathy in patients with malignant hypertension. Nephrol Dial Transplant. 2023;38(5):1217\u20131226. https:\/\/doi.org\/10.1093\/ndt\/gfac248. PMID: 36002030.","DOI":"10.1093\/ndt\/gfac248"},{"key":"4739_CR33","doi-asserted-by":"publisher","unstructured":"Palma LMP, Vaisbich-Guimar\u00e3es MH, Sridharan M, Tran CL, Sethi S. Thrombotic microangiopathy in children. Pediatr Nephrol. 2022;37(9):1967\u201380. https:\/\/doi.org\/10.1007\/s00467-021-05370-8.","DOI":"10.1007\/s00467-021-05370-8"},{"key":"4739_CR34","doi-asserted-by":"publisher","unstructured":"Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol. 2018;13(2):300\u201317. https:\/\/doi.org\/10.2215\/cjn.00620117.","DOI":"10.2215\/cjn.00620117"},{"key":"4739_CR35","doi-asserted-by":"publisher","unstructured":"Khandelwal P, Bagga A. Managing anti-factor H antibody-associated hemolytic uremic syndrome: time for consensus. Pediatr Nephrol. 2024;39(11):3137\u201341. https:\/\/doi.org\/10.1007\/s00467-024-06374-w.","DOI":"10.1007\/s00467-024-06374-w"},{"key":"4739_CR36","doi-asserted-by":"publisher","unstructured":"Seplveda RA, Tagle R, Jara A. Sindrome hemolitico Uremico Atipico. Rev Med Chile. 2018;146(6):770\u20139. https:\/\/doi.org\/10.4067\/s0034-98872018000600770.","DOI":"10.4067\/s0034-98872018000600770"},{"key":"4739_CR37","doi-asserted-by":"publisher","unstructured":"Clark SJ, Ridge LA, Herbert AP, et al. Tissue-Specific host recognition by complement factor H is mediated by differential activities of its Glycosaminoglycan-Binding regions. J Immunol. 2013;190(5):2049\u201357. https:\/\/doi.org\/10.4049\/jimmunol.1201751.","DOI":"10.4049\/jimmunol.1201751"},{"key":"4739_CR38","doi-asserted-by":"publisher","unstructured":"Vriese ASD, Sethi S, Praet JV, Nath KA, Fervenza FC. Kidney disease caused by dysregulation of the complement alternative pathway: an etiologic approach. J Am Soc Nephrol. 2015;26(12):2917\u201329. https:\/\/doi.org\/10.1681\/asn.2015020184.","DOI":"10.1681\/asn.2015020184"},{"key":"4739_CR39","doi-asserted-by":"publisher","unstructured":"Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012;8(11):622\u201333. https:\/\/doi.org\/10.1038\/nrneph.2012.195.","DOI":"10.1038\/nrneph.2012.195"},{"issue":"1","key":"4739_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/s0065-1281(96)80052-3","volume":"98","author":"P Bab\u00e1l","year":"1996","unstructured":"Bab\u00e1l P, Sluge\u0148 I, Dani\u0161 D, Jr. Zavia\u010di\u010d M, WAG. Sialic acid expression in normal and diseased human kidney. Acta Histochem. 1996;98(1):71\u20137. https:\/\/doi.org\/10.1016\/s0065-1281(96)80052-3.","journal-title":"Acta Histochem"},{"key":"4739_CR41","doi-asserted-by":"publisher","unstructured":"Bernabeu AIA, Escribano TC, Vilarino MC. Atypical hemolytic uremic syndrome: new challenges in the complement blockage era. Nephron. 2020;144(11):537\u201349. https:\/\/doi.org\/10.1159\/000508920.","DOI":"10.1159\/000508920"},{"issue":"S4","key":"4739_CR42","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1002\/ajh.26854","volume":"98","author":"J Leon","year":"2023","unstructured":"Leon J, LeStang M, Sberro-Soussan R, et al. Complement\u2010driven hemolytic uremic syndrome. Am J Hematol. 2023;98(S4):S44\u201356. https:\/\/doi.org\/10.1002\/ajh.26854.","journal-title":"Am J Hematol"},{"key":"4739_CR43","doi-asserted-by":"publisher","unstructured":"Feitz WJC, van de Kar NCAJ, Orth-H\u00f6ller D, van den Heuvel LPJW, Licht C. Genetik des atypischen h\u00e4molytisch-ur\u00e4mischen syndroms. Med Genet. 2018;30(4):400\u20139. https:\/\/doi.org\/10.1007\/s11825-018-0216-0.","DOI":"10.1007\/s11825-018-0216-0"},{"key":"4739_CR44","doi-asserted-by":"publisher","unstructured":"Michael M, Bagga A, Sartain SE, Smith RJH. Haemolytic uraemic syndrome. Lancet. 2022;400(10364):1722\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(22)01202-8.","DOI":"10.1016\/s0140-6736(22)01202-8"},{"key":"4739_CR45","doi-asserted-by":"publisher","unstructured":"Nayer A, Asif A. Atypical Hemolytic\u2013Uremic syndrome. Am J Ther. 2016;23(1):e151\u20138. https:\/\/doi.org\/10.1097\/mjt.0b013e31829b59dc.","DOI":"10.1097\/mjt.0b013e31829b59dc"},{"key":"4739_CR46","doi-asserted-by":"publisher","unstructured":"Schaefer F, Ardissino G, Ariceta G, et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int. 2018;94(2):408\u201318. https:\/\/doi.org\/10.1016\/j.kint.2018.02.029.","DOI":"10.1016\/j.kint.2018.02.029"},{"issue":"6","key":"4739_CR47","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.kint.2024.09.012","volume":"106","author":"D Kavanagh","year":"2024","unstructured":"Kavanagh D, Ardissino G, Brocklebank V, et al. Outcomes from the international society of nephrology hemolytic uremic syndromes international forum. Kidney Int. 2024;106(6):1038\u201350. https:\/\/doi.org\/10.1016\/j.kint.2024.09.012.","journal-title":"Kidney Int"},{"key":"4739_CR48","doi-asserted-by":"publisher","unstructured":"Gurevich E, Landau D. Pharmacological management of atypical hemolytic uremic syndrome in pediatric patients: current and future. Pediatr Drugs. 2023;25(2):193\u2013202. https:\/\/doi.org\/10.1007\/s40272-022-00555-6.","DOI":"10.1007\/s40272-022-00555-6"},{"issue":"6","key":"4739_CR49","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ejim.2013.05.008","volume":"24","author":"F Fakhouri","year":"2013","unstructured":"Fakhouri F, Fr\u00e9meaux-Bacchi V, Loirat C. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy. Eur J Intern Med. 2013;24(6):492\u20135. https:\/\/doi.org\/10.1016\/j.ejim.2013.05.008.","journal-title":"Eur J Intern Med"},{"issue":"10095","key":"4739_CR50","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/s0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Zuber J, Fr\u00e9meaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681\u201396. https:\/\/doi.org\/10.1016\/s0140-6736(17)30062-4.","journal-title":"Lancet"},{"key":"4739_CR51","doi-asserted-by":"publisher","unstructured":"Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15\u201339. https:\/\/doi.org\/10.1007\/s00467-015-3076-8.","DOI":"10.1007\/s00467-015-3076-8"},{"key":"4739_CR52","doi-asserted-by":"publisher","unstructured":"Syed YY, Ravulizumab. A review in atypical haemolytic uraemic syndrome. Drugs. 2021;81(5):587\u201394. https:\/\/doi.org\/10.1007\/s40265-021-01481-6.","DOI":"10.1007\/s40265-021-01481-6"},{"key":"4739_CR53","doi-asserted-by":"publisher","unstructured":"Tanaka K, Adams B, Aris AM, et al. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with Eculizumab. Pediatr Nephrol. 2021;36(4):889\u201398. https:\/\/doi.org\/10.1007\/s00467-020-04774-2.","DOI":"10.1007\/s00467-020-04774-2"},{"key":"4739_CR54","doi-asserted-by":"publisher","unstructured":"Barbour T, Scully M, Ariceta G, et al. Long-Term efficacy and safety of the Long-Acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults. Kidney Int Rep. 2021;6(6):1603\u201313. https:\/\/doi.org\/10.1016\/j.ekir.2021.03.884.","DOI":"10.1016\/j.ekir.2021.03.884"},{"key":"4739_CR55","doi-asserted-by":"publisher","unstructured":"Ariceta G, Dixon BP, Kim SH, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int. 2021;100(1):225\u201337. https:\/\/doi.org\/10.1016\/j.kint.2020.10.046.","DOI":"10.1016\/j.kint.2020.10.046"},{"issue":"8","key":"4739_CR56","doi-asserted-by":"publisher","first-page":"100855","DOI":"10.1016\/j.xkme.2024.100855","volume":"6","author":"BP Dixon","year":"2024","unstructured":"Dixon BP, Kavanagh D, Aris ADM, et al. Ravulizumab in atypical hemolytic uremic syndrome: an analysis of 2-Year efficacy and safety outcomes in 2 phase 3 trials. Kidney Med. 2024;6(8):100855. https:\/\/doi.org\/10.1016\/j.xkme.2024.100855.","journal-title":"Kidney Med"},{"key":"4739_CR57","doi-asserted-by":"publisher","unstructured":"Fakhouri F, Schwotzer N, Fr\u00e9meaux-Bacchi V. How I diagnose and treat atypical hemolytic uremic syndrome. Blood. 2023;141(9):984\u2013995. https:\/\/doi.org\/10.1182\/blood.2022017860.","DOI":"10.1182\/blood.2022017860"},{"key":"4739_CR58","doi-asserted-by":"publisher","unstructured":"Macia M, Moreno F, de Dutt A. Current evidence on the discontinuation of Eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J. 2017;10(3):sfw115. https:\/\/doi.org\/10.1093\/ckj\/sfw115.","DOI":"10.1093\/ckj\/sfw115"},{"key":"4739_CR59","doi-asserted-by":"publisher","unstructured":"Fakhouri F, Fila M, Hummel A, et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood. 2021;137(18):2438\u201349. https:\/\/doi.org\/10.1182\/blood.2020009280.","DOI":"10.1182\/blood.2020009280"},{"key":"4739_CR60","doi-asserted-by":"publisher","unstructured":"Ariceta G, Fakhouri F, Sartz L, et al. Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes. Clin Kidney J. 2021;14(9):2075\u201384. https:\/\/doi.org\/10.1093\/ckj\/sfab005.","DOI":"10.1093\/ckj\/sfab005"},{"key":"4739_CR61","doi-asserted-by":"publisher","unstructured":"Imanifard Z, Liguori L, Remuzzi G. TMA in Kidney Transplantation. Transplantation. 2023;107(11):2329\u20132340. https:\/\/doi.org\/10.1097\/TP.0000000000004585. Epub 2023 Oct 21. PMID: 36944606.","DOI":"10.1097\/TP.0000000000004585"},{"issue":"4","key":"4739_CR62","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1097\/TP.0000000000004355","volume":"107","author":"EK Glover","year":"2023","unstructured":"Glover EK, Smith-Jackson K, Brocklebank V, Wilson V, Walsh PR, Montgomery EK, Wong EKS, Johnson S, Malina M, Kavanagh D, Sheerin NS, UK aHUS Transplant Consortium. Assessing the impact of prophylactic Eculizumab on renal graft survival in atypical hemolytic uremic syndrome. Transplantation. 2023;107(4):994\u20131003. https:\/\/doi.org\/10.1097\/TP.0000000000004355. Epub 2023 Mar 31.","journal-title":"Transplantation"},{"key":"4739_CR63","doi-asserted-by":"publisher","unstructured":"Campistol JM, Arias M, Ariceta G, et al. Actualizaci\u00f3n En s\u00edndrome hemol\u00edtico ur\u00e9mico at\u00edpico: diagn\u00f3stico y tratamiento. Documento de consenso. Nefrolog\u00eda. 2015;35(5):421\u201347. https:\/\/doi.org\/10.1016\/j.nefro.2015.07.005.","DOI":"10.1016\/j.nefro.2015.07.005"},{"key":"4739_CR64","doi-asserted-by":"publisher","unstructured":"Benamu E, Montoya JG. Infections associated with the use of Eculizumab. Curr Opin Infect Dis. 2016;29(4):319\u201329. https:\/\/doi.org\/10.1097\/qco.0000000000000279.","DOI":"10.1097\/qco.0000000000000279"},{"key":"4739_CR65","doi-asserted-by":"publisher","first-page":"931210","DOI":"10.3389\/fimmu.2022.931210","volume":"13","author":"R Raina","year":"2022","unstructured":"Raina R, Mangat G, Hong G, et al. Anti-factor H antibody and its role in atypical hemolytic uremic syndrome. Front Immunol. 2022;13:931210. https:\/\/doi.org\/10.3389\/fimmu.2022.931210.","journal-title":"Front Immunol"},{"key":"4739_CR66","doi-asserted-by":"publisher","first-page":"103216","DOI":"10.1016\/j.jaut.2024.103216","volume":"145","author":"K Watanabe-Kusunoki","year":"2024","unstructured":"Watanabe-Kusunoki K, Anders HJ. Balancing efficacy and safety of complement inhibitors. J Autoimmun. 2024;145:103216. https:\/\/doi.org\/10.1016\/j.jaut.2024.103216.","journal-title":"J Autoimmun"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04739-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04739-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04739-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T14:32:14Z","timestamp":1767882734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-025-04739-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4739"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04739-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as this is not original research involving patients or human participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and consent to publish"}},{"value":"This work is based on a structured literature review and expert discussion; it does not involve interventions in humans. Hence, specific research ethics standards (e.g., Declaration of Helsinki) do not apply. All data generated during the consensus process are included within the article and supplementary files.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Standards or norms observed"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}